Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Clinical trial NCT06282978 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06282978
- Sponsor
- PETHEMA Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-23
- Primary completion
- 2025-05-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.